Literature DB >> 18359195

Cancer cachexia: measured and predicted resting energy expenditures for nutritional needs evaluation.

Gyasi Johnson1, Agnès Sallé, Gérard Lorimier, Laurent Laccourreye, Bernard Enon, Vincent Blin, Yann Jousset, Jean-Pierre Arnaud, Yves Malthièry, Gilles Simard, Patrick Ritz.   

Abstract

OBJECTIVE: Cancer cachexia is associated with weight loss, poor nutritional status, and systemic inflammation. Accurate nutritional support for patients is calculated on resting energy expenditure (REE) measurement or prediction. The present study evaluated the agreement between measured and predicted REE (mREE and pREE, respectively) and the influence of acute phase response (APR) on REE.
METHODS: Thirty-six patients with cancer were divided into weight-stable (WS; weight loss <2%) and weight-losing (WL; weight loss >5%) patients. Measured REE was measured by indirect calorimetry and adjusted for fat-free mass (FFM). The Bland-Altman approach was used to assess the agreement between mREE and pREE from the Harris-Benedict equations (HBE). Blood levels of C-reactive protein were assessed.
RESULTS: There was no difference in mREE between groups (WS 1677 +/- 273, WL 1521 +/- 305) even when mREE was adjusted for FFM (WS 1609 +/- 53, WL 1589 +/- 53). In WL patients, FFM-adjusted REE correlated with blood C-reactive protein levels (r = 0.471, P = 0.048). HBEs tend to underestimate REE in both groups.
CONCLUSION: WL and WS patients with cancer had similar REEs but were different in terms of APR. APR could contribute to weight loss through enhancing REE. In a clinical context, HBE was in poor agreement with mREE in both groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359195     DOI: 10.1016/j.nut.2008.01.013

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  12 in total

Review 1.  Key determinants of energy expenditure in cancer and implications for clinical practice.

Authors:  S A Purcell; S A Elliott; V E Baracos; Q S C Chu; C M Prado
Journal:  Eur J Clin Nutr       Date:  2016-06-08       Impact factor: 4.016

2.  Symptoms in advanced pancreatic cancer are of importance for energy intake.

Authors:  Asta Bye; Marit S Jordhøy; Grete Skjegstad; Oddlaug Ledsaak; Per Ole Iversen; Marianne Jensen Hjermstad
Journal:  Support Care Cancer       Date:  2012-06-10       Impact factor: 3.603

3.  Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme.

Authors:  Rebecca B Little; Robert A Oster; Betty E Darnell; Wendy Demark-Wahnefried; L Burt Nabors
Journal:  Nutr Cancer       Date:  2016-06-24       Impact factor: 2.900

4.  Energy expenditure in the critically ill performing early physical therapy.

Authors:  Cheryl E Hickmann; Jean Roeseler; Diego Castanares-Zapatero; Eduardo I Herrera; Arthur Mongodin; Pierre-François Laterre
Journal:  Intensive Care Med       Date:  2014-01-30       Impact factor: 17.440

Review 5.  Evidence and mechanisms of fat depletion in cancer.

Authors:  Maryam Ebadi; Vera C Mazurak
Journal:  Nutrients       Date:  2014-11-19       Impact factor: 5.717

6.  The prognostic influence of body mass index, resting energy expenditure and fasting blood glucose on postoperative patients with esophageal cancer.

Authors:  Ning Wu; Yongjun Zhu; Dhruba Kadel; Liewen Pang; Gang Chen; Zhiming Chen
Journal:  BMC Gastroenterol       Date:  2016-12-21       Impact factor: 3.067

7.  Effects of Serum Leptin and Resistin Levels on Cancer Cachexia in Patients With Advanced-Stage Non-Small Cell Lung Cancer.

Authors:  Gökcen Demiray; Serkan Değirmencioğlu; Erhan Uğurlu; Arzu Yaren
Journal:  Clin Med Insights Oncol       Date:  2017-02-20

Review 8.  Updates on the pathogenesis of advanced lung cancer-induced cachexia.

Authors:  Ruifang Zhu; Zhihong Liu; Ran Jiao; Chichen Zhang; Qi Yu; Shifan Han; Zhiguang Duan
Journal:  Thorac Cancer       Date:  2018-11-20       Impact factor: 3.500

9.  Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.

Authors:  Hitomi Jo; Tatsuya Yoshida; Hidehito Horinouchi; Shigehiro Yagishita; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Noboru Yamamoto; Kazuhisa Takahashi; Noriko Motoi; Yuichiro Ohe
Journal:  Cancer Immunol Immunother       Date:  2021-06-27       Impact factor: 6.968

Review 10.  The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review.

Authors:  Paolo Bossi; Paolo Delrio; Annalisa Mascheroni; Michela Zanetti
Journal:  Nutrients       Date:  2021-06-09       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.